ERBB2 and bone metastasis: For the HER2‐low group of 597 patients, the most frequent metastatic sites were bone, liver, and lung in which there were 57 (9.5%) patients with bone metastasis, 40 (6.7%) patients with liver metastasis, and 38 (6.4%) patients with lung metastasis.